New Ray Medicine International Holding Limited provided consolidated earnings guidance for the six months ended 30 June 2022. It is expected that the Group will record a loss of over HKD 21 million for the six months ended 30 June 2022 as compared to a profit of approximately HKD 1.1 million recorded by the Group for the six months ended 30 June 2021. The expected loss of the Group for 1H 2022 was primarily due to (i) the decrease in the gross profit owing to the decrease in the revenue of the Group's major product under the second generation of Cephalosporins (1.0g) as a result of (a) the resurgence of coronavirus disease (Covid-19) cases in the mainland China in 1H 2022 causing the slowdown in trading activities and business operations of the Group and (b) the adverse impact from the further strengthened policy on the adoption of stratified and categorised management of antibacterial drugs in various regions in mainland China; (ii) the decrease in gross profit margin owing to the decrease in sales volume of the Product along with the fixed amortisation costs, classified as cost of sales, remain unchanged for 1H 2022; (iii) the recognition of equity-settled share-based payment expenses of approximately HKD 10.4 million for the grant of share options by the Group to the Directors and employees in June 2022; and (iv) the recognition of the net exchange losses of approximately HKD 6.9 million for 1H 2022 as compared to the net exchange gain of approximately HKD 1.8 million for 1H 2021.